Literature DB >> 1517576

Tumor target-derived soluble factor synergizes with IFN-gamma and IL-2 to activate macrophages for tumor necrosis factor and nitric oxide production to mediate cytotoxicity of the same target.

H Jiang1, C A Stewart, D J Fast, R W Leu.   

Abstract

Inflammatory mouse peritoneal macrophages were activated by IFN-gamma in synergy with IL-2 or Lipid A to mediate TNF production for autocrine generation of cytotoxic nitric oxide (NO) to kill P815 or L1210 tumor targets. It was determined that for IL-2, but not Lipid A, to effectively trigger activation of IFN-gamma-primed macrophages, the tumor targets must be also present for interaction with effector macrophages to mediate the production of TNF and NO. IFN-gamma- and IL-2-activated macrophages from syngeneic DBA/2 and allogeneic C3H mice had identical MHC-unrestricted requirements for interaction with DBA/2 mouse-derived P815 and L1210 targets to mediate production of TNF and NO for tumor cytotoxicity. To further define the mechanistic requirements for macrophage-tumor target interaction, IFN-gamma- and IL-2-activated macrophages were separated from P815 targets in culture by a semipermeable membrane. Under these conditions, both TNF and NO were produced by the macrophage, which indicated that the requirement for tumor target-macrophage interaction may be due to a soluble factor produced by the target rather than to direct physical contact. This was confirmed by experiments in which 24-h cell-free culture fluids, derived from either P815 or L1210 tumor targets, substituted for the intact tumor cells in the stimulation of TNF mRNA synthesis and secretion with NO generation of TNF mRNA synthesis and secretion with NO generation by IFN-gamma- and IL-2-activated C3H or DBA/2 macrophages. The activity in 24-h culture fluids derived from P815 and L1210 tumor targets was tentatively designated as tumor-derived recognition factor(s) (TDRF) since it was produced constitutively by the tumor targets and synergized with IFN-gamma and IL-2 to induce macrophage production of TNF and NO for death of the same targets. A variety of nontransformed human and mouse fibroblasts, mouse spleen lymphocytes, and two adherent mouse fibrosarcomas did not produce detectable TDRF activity, whereas two mouse T lymphomas, EL4 and EL4.IL-2, produced TDRF activity similar to L1210 mouse leukemia and P815 mastocytoma. The C3H/MCA, a TDRF-nonproducing mouse fibrosarcoma, was susceptible to cytotoxicity mediated by macrophages activated by IFN-gamma and Lipid A, but not by IL-2 triggering. Exogenous TDRF derived from L1210 targets reconstituted the cytotoxic activity for C3H/MCA MCA targets mediated by IFN-gamma- and IL-2-activated macrophages accompanied by the production of TNF and cytotoxic NO.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1517576

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Analysis of the in vitro effect of exogenous nitric oxide on human lymphocytes.

Authors:  A S Shoker; H Yang; M A Murabit; H Jamil; A al-Ghoul; K Okasha
Journal:  Mol Cell Biochem       Date:  1997-06       Impact factor: 3.396

2.  Tumour necrosis factor alpha is elevated in serum and cerebrospinal fluid in multiple sclerosis and inflammatory neuropathies.

Authors:  M Rentzos; C Nikolaou; A Rombos; K Voumvourakis; I Segditsa; C Papageorgiou
Journal:  J Neurol       Date:  1996-02       Impact factor: 4.849

Review 3.  The dichotomous role of H2S in cancer cell biology? Déjà vu all over again.

Authors:  Khosrow Kashfi
Journal:  Biochem Pharmacol       Date:  2018-02-14       Impact factor: 5.858

4.  KRAS mutation and epithelial-macrophage interplay in pancreatic neoplastic transformation.

Authors:  Faraz Bishehsari; Lijuan Zhang; Usman Barlass; Nailliw Z Preite; Sanja Turturro; Matthew S Najor; Brandon B Shetuni; Janet P Zayas; Mahboobeh Mahdavinia; Abde M Abukhdeir; Ali Keshavarzian
Journal:  Int J Cancer       Date:  2018-08-09       Impact factor: 7.396

5.  Macrophages produce nitric oxide at allograft sites.

Authors:  J M Langrehr; D A White; R A Hoffman; R L Simmons
Journal:  Ann Surg       Date:  1993-08       Impact factor: 12.969

6.  Nonspecific immunotherapy with intratumoral lipopolysaccharide and zymosan A but not GM-CSF leads to an effective anti-tumor response in subcutaneous RG-2 gliomas.

Authors:  Christopher L Mariani; Didier Rajon; Francis J Bova; Wolfgang J Streit
Journal:  J Neurooncol       Date:  2007-06-14       Impact factor: 4.130

Review 7.  Macrophage Reprogramming and Cancer Therapeutics: Role of iNOS-Derived NO.

Authors:  Khosrow Kashfi; Jasmine Kannikal; Niharika Nath
Journal:  Cells       Date:  2021-11-16       Impact factor: 6.600

8.  Modulation of nitric oxide synthase activity in macrophages.

Authors:  P G Jorens; K E Matthys; H Bult
Journal:  Mediators Inflamm       Date:  1995       Impact factor: 4.711

Review 9.  The dual role of iNOS in cancer.

Authors:  Federica Vannini; Khosrow Kashfi; Niharika Nath
Journal:  Redox Biol       Date:  2015-08-24       Impact factor: 11.799

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.